Skip to main content
. 2021 Jan 15;7(3):eabc4897. doi: 10.1126/sciadv.abc4897

Fig. 1. Identification of a compound that kills cancer cells independent of BAX/BAK.

Fig. 1

(A) Schematic of the phenotypical screen. MDA231 cells were transfected with two siRNAs against BAX and BAK proteins. The MDA231 and MCF10a were treated with 30,000 small molecules in duplicate from diverse libraries. (B) Cell viability of the MCF10a and MDA231 (BAX/BAK siRNA) cells for each of the 30,000 compounds test. Blue dots indicate the compounds that were cherry picked for a secondary screen. (C) The fold change in response of the MDA231 cells to cherry-picked compounds compared with MCF10a cells. (D) Pie chart represents the number of compounds that showed a response in the indicated cells. (E) Cell survival of the indicated cell lines following a 48-hour treatment with BAS-2 (n = 3, mean ± SEM). (F) Chemical structure of the lead compound, BAS-2. (G) Cell survival of the indicated cell lines following a 48-hour treatment with BAS-2 (n = 3, mean ± SEM).